ATE135908T1 - Optisch reines r(-)albuterol zur behandlung von asthma - Google Patents

Optisch reines r(-)albuterol zur behandlung von asthma

Info

Publication number
ATE135908T1
ATE135908T1 AT91902520T AT91902520T ATE135908T1 AT E135908 T1 ATE135908 T1 AT E135908T1 AT 91902520 T AT91902520 T AT 91902520T AT 91902520 T AT91902520 T AT 91902520T AT E135908 T1 ATE135908 T1 AT E135908T1
Authority
AT
Austria
Prior art keywords
albuterol
asthma
optically pure
treatment
isomer
Prior art date
Application number
AT91902520T
Other languages
English (en)
Inventor
Timothy J Barberich
James W Young
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23831837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE135908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ATE135908T1 publication Critical patent/ATE135908T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT91902520T 1990-01-05 1991-01-04 Optisch reines r(-)albuterol zur behandlung von asthma ATE135908T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46126290A 1990-01-05 1990-01-05

Publications (1)

Publication Number Publication Date
ATE135908T1 true ATE135908T1 (de) 1996-04-15

Family

ID=23831837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91902520T ATE135908T1 (de) 1990-01-05 1991-01-04 Optisch reines r(-)albuterol zur behandlung von asthma

Country Status (11)

Country Link
US (1) US6083993A (de)
EP (1) EP0509036B1 (de)
JP (1) JP3085705B2 (de)
AT (1) ATE135908T1 (de)
AU (1) AU7174191A (de)
CA (1) CA2073181C (de)
DE (1) DE69118359T2 (de)
DK (1) DK0509036T3 (de)
ES (1) ES2085468T3 (de)
GR (1) GR3020133T3 (de)
WO (1) WO1991009596A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2289842B (en) * 1991-04-05 1996-01-31 Sepracor Inc Improved use of ß2 bronchodilator drugs
GB9107196D0 (en) * 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
CA2286913C (en) * 1997-04-30 2008-12-09 Bridge Pharma, Inc. Composition and methods using an eutomer
WO1999042460A1 (en) * 1998-02-20 1999-08-26 Fine Chemicals Corporation (Proprietary) Limited Process for the production of optically enriched (r)- or (s)-albuterol
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
US7232837B2 (en) 1999-06-29 2007-06-19 Mcneil-Ppc, Inc. Stereoisomers with high affinity for adrenergic receptors
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
AU2003226603A1 (en) * 2002-04-19 2003-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
EP1562975A2 (de) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroide welche gruppen zur nachahmung von superoxidase dismutase sowie stickoxid donorgruppen beinhalten und ihre verwendung in der darstellung von medikamenten
US20050020692A1 (en) * 2003-07-24 2005-01-27 Ciofalo Vincent B. Treatment of heaves
NZ547178A (en) * 2003-11-20 2008-06-30 Alteragon Pty Ltd Method of decreasing fat deposits and body weight in mammals and birdsusing the R-isomer of Salbutamol
CA2570386A1 (en) * 2004-06-14 2005-12-29 Sepracor Inc. Methods of using albuterol and calcium activated potassium channel openers
WO2005123072A1 (en) * 2004-06-14 2005-12-29 Sepracor Inc. Methods and compositions for the treatment of pulmonary diseases
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
WO2012087094A1 (es) * 2010-12-21 2012-06-28 Techsphere S.A. De C.V. Composición farmacéutica inhalable para el tratamiento del asma por administración vía aérea mediante un succionador de emulación de aerosol
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
EP4651867A1 (de) 2023-01-20 2025-11-26 Atrogi AB Beta 2-adrenergische rezeptoragonisten zur behandlung oder prävention von muskelschwund
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1298494A (en) * 1970-06-17 1972-12-06 Allen & Hanburys Ltd Phenylethanolamine derivatives
US4965065A (en) * 1986-04-29 1990-10-23 Bristol-Myers Squibb Company Gastroprotective process and compositions
EP0320550A1 (de) * 1987-12-18 1989-06-21 Bristol-Myers Company NSAID-Zusammensetzungen mit Gehalt an H1-Blockern, H2-Blockern, beta-adrenergischen Agonisten oder Mischungen hiervon und an einem Alkalinisierungsmittel
GB9107196D0 (en) * 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
JP3085705B2 (ja) 2000-09-11
EP0509036A1 (de) 1992-10-21
WO1991009596A1 (en) 1991-07-11
DE69118359D1 (de) 1996-05-02
AU7174191A (en) 1991-07-24
DK0509036T3 (da) 1996-07-29
CA2073181C (en) 2002-04-23
GR3020133T3 (en) 1996-08-31
EP0509036B1 (de) 1996-03-27
DE69118359T2 (de) 1996-08-14
US6083993A (en) 2000-07-04
ES2085468T3 (es) 1996-06-01
JPH05503102A (ja) 1993-05-27
CA2073181A1 (en) 1991-07-06

Similar Documents

Publication Publication Date Title
ATE135908T1 (de) Optisch reines r(-)albuterol zur behandlung von asthma
EP0792156A4 (de) Verfahren zur vorbeugung oder behandlung von vaskulären hämorragien und der alzheimerischen krankheit
DE69032579D1 (de) Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin-assoziierten storungen
DE3855525D1 (de) Verwendung eines Protein gebundenen Polysaccharid Zur Herstellung eines Arzneimittels für die Behandlung von AIDS.
RU94036748A (ru) Церамиды, способ их получения, композиция на их основе и способ гидратирующей обработки кожи или волос
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE69628912D1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
DE69829112D1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
DE60016461D1 (de) Verfahren zur behandlung von glassubstraten und glassubstraten zur herstellung von anzeigeschirmen
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
ATE126441T1 (de) Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69703617D1 (de) Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
DE3875575D1 (de) Verfahren und vorrichtung und vorrichtung zur herstellung und behandlung von transfermembranen.
DE69003009D1 (de) Verfahren zur Behandlung von Fasermaterialien.
ATE213252T1 (de) Verfahren zur herstellung eines inter-alpha- trypsin inhibitor konzentrats mit therapeutischer anwendung und so erhaltenes konzentrat
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
KR890701099A (ko) 기침 및 기관지 협착을 치료하기 위한 5-ht3 수용기 길항물질
ATE268166T1 (de) Zusammenstellungen zur behandlung von lungenkrankheiten mit optisch reinem s-salmeterol
DE69619187D1 (de) Verfahren zur behandlung von motorischen defiziten
ATE71307T1 (de) Verfahren zur behandlung von kontaktlinsen.
AU2824289A (en) Thienotricyclene for the treatment of bronchial diseases
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time